Header Logo

Connection

ZOANN DREYER to Protein Kinase Inhibitors

Back to Details
This is a "connection" page, showing publications ZOANN DREYER has written about Protein Kinase Inhibitors.
ZOANN DREYER
Connection Strength
0.137
Protein Kinase Inhibitors
  1. FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631. Leukemia. 2021 05; 35(5):1279-1290.
    View in: PubMed
    Score: 0.137
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.